Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.67 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.67 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.67 |
| ▸ | CD69 | Q07108 | 1/20 | 0.55 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.51 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.51 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.49 |
| ▸ | AMY2A | P04746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466465 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL19241971 | 0.98 | LGALS3 (0.64) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL4309100 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL20555908 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL17050874 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL10524839 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL4125477 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL117333 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL14268473 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL9398176 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552876-B2 | Anti-fucosyl-GM1 antibodies | SCANCELL LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| US-20260042998-A1 | Glyco-Engineered Yeast for Therapeutic Protein Production | VIB VZW (BE) | 2026-02-12 | — | — | US | disclosed |
| WO-2025226970-A2 | LY6G6D BINDING PROTEINS, NUCLEIC ACIDS ENCODING SUCH PROTEINS, AND METHODS FOR THE PREPARATION AND USE THEREOF | CARTOGRAPHY BIOSCIENCES, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4025612-B1 | ANTI-FUCOSYL-GM1 ANTIBODIES | SCANCELL LTD (GB) | 2025-10-29 | — | — | EP | disclosed |
| EP-4469590-A1 | GLYCOENGINEERING OF THERMOTHELOMYCES HETEROTHALLICA | Dyadic International (USA), Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024039740-A2 | POLYPEPTIDE COMPOSITIONS CONTAINING NON-STANDARD GLYCAN STUB AMINO ACIDS AND METHODS OF MAKING AND USES THEREOF | GRO BIOSCIENCES INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024032891-A1 | GLYCO-ENGINEERED YEAST FOR THERAPEUTIC PROTEIN PRODUCTION | VIB VZW (BE) | 2024-02-15 | — | — | WO | disclosed |
| EP-4291232-A2 | ANTIBODIES THAT BIND METAPNEUMOVIRUS, ANTIGENIC METAPNEUMOVIRUS PROTEINS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023144739-A1 | GLYCOENGINEERING OF THERMOTHELOMYCES HETEROTHALLICA | DYADIC INTERNATIONAL (USA), INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20220267466-A1 | ANTI-FUCOSYL-GM1 ANTIBODIES | SCANCELL LIMITED (GB) | 2022-08-25 | — | — | US | disclosed |
| WO-2022173714-A2 | ANTIBODIES THAT BIND METAPNEUMOVIRUS, ANTIGENIC METAPNEUMOVIRUS PROTEINS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-2986644-B1 | V3 IMMUNOGENS | UNIV DUKE (US) | 2022-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552876-B2 | Anti-fucosyl-GM1 antibodies | FUCA1, FUCA2, SIGLEC7 | LGALS3 165/4885LGALS8 488/4885LGALS4 159/4885 |
| US-20260042998-A1 | Glyco-Engineered Yeast for Therapeutic Protein Production | MAN2A1, OGA, ERG28 | LGALS3 827/4885LGALS8 656/4885LGALS4 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.